Ser749

Site Information
QQRMENLsMFLIKRR SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 18016585

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 )
Disease tissue studied:	cervical cancer ( 1 ) , cervical adenocarcinoma ( 1 ) , lung cancer ( 3 , 4 ) , non-small cell lung cancer ( 3 , 4 )
Relevant cell line - cell type - tissue:	HeLa S3 (cervical) ( 1 ) , K562 (erythroid) ( 2 ) , lung ( 3 , 4 )

Upstream Regulation
Treatments:	dasatinib ( 2 )

References
1	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
2	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
3	Rikova K (2008) CST Curation Set: 4041; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
4	Rikova K (2008) CST Curation Set: 3686; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info